Baker Heart and Diabetes Institute

Diamyd Medical partners with JDRF to advance the DIAGNODE-3 Phase 3 trial in Type 1 Diabetes

Retrieved on: 
Tuesday, April 4, 2023
Baker Heart and Diabetes Institute, JDRF, Diamyd Medical, Insulin, National Rural Development Partnership, University, Therapy, Research, Disease, Medicine, Pharmaceutical industry

STOCKHOLM, April 4, 2023 /PRNewswire/ -- Diamyd Medical and JDRF, the leading global type 1 diabetes research and advocacy organization, have entered into a four-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd®.

Key Points: 
  • STOCKHOLM, April 4, 2023 /PRNewswire/ -- Diamyd Medical and JDRF, the leading global type 1 diabetes research and advocacy organization, have entered into a four-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd®.
  • "JDRF is committed to supporting and advancing disease modifying therapies to delay and reverse type 1 diabetes," said Sanjoy Dutta, Ph.D., chief scientific officer at JDRF.
  • "We are excited about Diamyd Medical's groundbreaking Phase 3 trial and its potential advancements in the preservation of insulin production for people recently diagnosed with type 1 diabetes."
  • "JDRF's commitment to this Phase 3 program is a validation of the scientific and clinical value of the antigen-specific immunotherapy Diamyd.

Diamyd Medical partners with JDRF to advance the DIAGNODE-3 Phase 3 trial in Type 1 Diabetes

Retrieved on: 
Tuesday, April 4, 2023
Baker Heart and Diabetes Institute, JDRF, Diamyd Medical, Insulin, National Rural Development Partnership, University, Therapy, Research, Disease, Medicine, Pharmaceutical industry

STOCKHOLM, April 4, 2023 /PRNewswire/ -- Diamyd Medical and JDRF, the leading global type 1 diabetes research and advocacy organization, have entered into a four-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd®.

Key Points: 
  • STOCKHOLM, April 4, 2023 /PRNewswire/ -- Diamyd Medical and JDRF, the leading global type 1 diabetes research and advocacy organization, have entered into a four-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd®.
  • "JDRF is committed to supporting and advancing disease modifying therapies to delay and reverse type 1 diabetes," said Sanjoy Dutta, Ph.D., chief scientific officer at JDRF.
  • "We are excited about Diamyd Medical's groundbreaking Phase 3 trial and its potential advancements in the preservation of insulin production for people recently diagnosed with type 1 diabetes."
  • "JDRF's commitment to this Phase 3 program is a validation of the scientific and clinical value of the antigen-specific immunotherapy Diamyd.

Global Cardiovascular Ultrasound Market Report 2022 to 2030 - Featuring GE Healthcare, Koninklijke Philips, Siemens Healthcare and Canon Medical Systems Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022
Health, Medical Devices, Cardiology, Degenerative disease, Heart, 2D, National Centers for Environmental Information, Modality, Baker Heart and Diabetes Institute, Moyamoya disease, National Center for Biotechnology Information, Blood, Prevalence, US, 3D, Time-invariant system, Heart valve, Growth, Marketing, Region, Doppler imaging, Medical imaging, Doppler effect

The "Cardiovascular Ultrasound Market, by Test Type, by Technology, by Modality, by End-user, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiovascular Ultrasound Market, by Test Type, by Technology, by Modality, by End-user, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • A cardiovascular ultrasound is a type of ultrasound that focuses on heart and blood vessels.
  • In echocardiogram tests, this type of imaging can be used to assess the function of various parts of cardiovascular system.
  • The emerging prevalence of cardiovascular diseases will surge the demand for cardiovascular ultrasound tests, which is expected to bolster the growth of global cardiovascular ultrasound market.

Hyloris Expands Cardiovascular Pipeline with Breakthrough Extended-Release Milrinone Capsule in Late-Stage Heart Failure

Retrieved on: 
Friday, October 8, 2021
Cardiovascular disease, Baker Institute, Center, NYHA, Atrial fibrillation, AHA, Diabetes, Milrinone, Safety, Population, Degenerative disease, Quality of life, Blood pressure, Minnesota, The Alfred Hospital, Company, Intellectual property, Baker Heart and Diabetes Institute, History, IV, HF, Plasma, Cardiology, LinkedIn, FDA, Issuer, CDC, Continuity, Ageing, Disease, Cardiomyopathy, Heart failure, ER, Arrhythmia, Classification, LVAD, Heart, R, PK, Life expectancy, Euronext, Oxygen, Heart rate, Risk, Acute decompensated heart failure, American Heart Association, Journal, Department, New York Heart Association Functional Classification, Blood, Diagnosis, Industry, Digoxin, Heart transplantation, Patient, Muscle tissue, Pharmaceutical industry, Medical device

Milrinone is a positive inotrope, a group of heart failure drugs that strengthen the hearts contractions so it can pump more blood with fewer heartbeats.

Key Points: 
  • Milrinone is a positive inotrope, a group of heart failure drugs that strengthen the hearts contractions so it can pump more blood with fewer heartbeats.
  • Milrinone IV is currently approved for use as an intermittent or continuous infusion for treatment of up to 48 hours for acute decompensated heart failure.
  • The current standard of care is predominantly palliative and despite recent advantages with new heart failure therapies, the effectiveness of these is most pronounced in mild to moderate heart failure.
  • 5 The New York Heart Association (NYHA) Classification provides a way of classifying the extent of heart failure.

Global Academic Research Organization UCL Selects Phlexglobal's Innovative eTMF Solution to Enhance TMF Compliance and Inspection-Readiness Across Entire Study Portfolio

Retrieved on: 
Wednesday, July 28, 2021
Health sciences, Health, Clinical research, Design of experiments, Medical research, Clinical pharmacology, Clinical trial, Pharmaceutical industry

PhlexTMF will support the entire portfolio at UCL's Institute of Clinical Trials and Methodology (ICTM), a pre-eminent center for clinical trials and amongst the largest of its kind in Europe.

Key Points: 
  • PhlexTMF will support the entire portfolio at UCL's Institute of Clinical Trials and Methodology (ICTM), a pre-eminent center for clinical trials and amongst the largest of its kind in Europe.
  • The decision by the UCL team followed a comprehensive tendering process with Phlexglobal appointed as the preferred bidder to help UCL streamline TMF management and oversight while reducing cost and risk.
  • "We're honored that a highly respected research organization like UCL selected Phlexglobal for their eTMF solution," said John McNeill, Chief Executive Officer of Phlexglobal.
  • The Institute of Clinical Trials and Methodology at UCL is a centre of excellence for clinical trials, meta analysis and epidemiological studies.